Filtered By:
Vaccination: Covid Vaccine
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 26665 results found since Jan 2013.
The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022
ConclusionEnhanced testing for respiratory viruses during the COVID-19 pandemic provided a more complete picture of influenza virus transmission compared with previous seasons. Returned international travellers were important drivers of influenza reemergence, as were young adults, a group whose role has previously been under-recognised in the establishment of seasonal influenza epidemics. Targeting interventions, including vaccination, to these groups could reduce future influenza transmission.PMID:37707981 | DOI:10.2807/1560-7917.ES.2023.28.37.2300118
Source: Euro Surveill - September 14, 2023 Category: Infectious Diseases Authors: Catherine Ga Pendrey Janet Strachan Heidi Peck Ammar Aziz Jean Moselen Rob Moss Md Rezanur Rahaman Ian G Barr Kanta Subbarao Sheena G Sullivan Source Type: research
Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Biologicals. 2023 Sep 12;84:101700. doi: 10.1016/j.biologicals.2023.101700. Online ahead of print.ABSTRACTIn recent years, urgent unmet medical needs due to the COVID-19 pandemic have accelerated the application of mRNA technology in vaccine development, leading to some of the first approvals of mRNA vaccines in human history by regulatory agencies around the world. For market authorization, comprehensive chemistry, manufacturing and control (CMC) information is required to assure the safety and quality consistency of mRNA vaccines. Evaluating mRNA vaccines for new virus variants poses a challenge for regulators, given the...
Source: Biologicals : Journal of the International Association of Biological Standardization - September 14, 2023 Category: Biotechnology Authors: Jiaqi Lu Wei Wei Wu He Source Type: research
The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022
ConclusionEnhanced testing for respiratory viruses during the COVID-19 pandemic provided a more complete picture of influenza virus transmission compared with previous seasons. Returned international travellers were important drivers of influenza reemergence, as were young adults, a group whose role has previously been under-recognised in the establishment of seasonal influenza epidemics. Targeting interventions, including vaccination, to these groups could reduce future influenza transmission.PMID:37707981 | DOI:10.2807/1560-7917.ES.2023.28.37.2300118
Source: Euro Surveill - September 14, 2023 Category: Infectious Diseases Authors: Catherine Ga Pendrey Janet Strachan Heidi Peck Ammar Aziz Jean Moselen Rob Moss Md Rezanur Rahaman Ian G Barr Kanta Subbarao Sheena G Sullivan Source Type: research
Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Biologicals. 2023 Sep 12;84:101700. doi: 10.1016/j.biologicals.2023.101700. Online ahead of print.ABSTRACTIn recent years, urgent unmet medical needs due to the COVID-19 pandemic have accelerated the application of mRNA technology in vaccine development, leading to some of the first approvals of mRNA vaccines in human history by regulatory agencies around the world. For market authorization, comprehensive chemistry, manufacturing and control (CMC) information is required to assure the safety and quality consistency of mRNA vaccines. Evaluating mRNA vaccines for new virus variants poses a challenge for regulators, given the...
Source: Biologicals : Journal of the International Association of Biological Standardization - September 14, 2023 Category: Biotechnology Authors: Jiaqi Lu Wei Wei Wu He Source Type: research
Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development
J Immunol Methods. 2023 Sep 11:113558. doi: 10.1016/j.jim.2023.113558. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an enveloped, plus-stranded RNA virus responsible for the Coronavirus Disease 2019 (COVID-19). Patients infected with COVID-19 may be asymptomatic or have symptoms ranging from mild manifestations to severe cases of the disease that could lead to death. The SARS-CoV-2 genome encodes 4 structural proteins, including the Spike protein (S), the Nucleocapsid protein (N), membrane protein (M) and, the envelope (E). The N protein forms a major component of the ribonu...
Source: Journal of Immunological Methods - September 13, 2023 Category: Allergy & Immunology Authors: Michelle Teixeira de Almeida Ana Paula Barbosa Camila Gasque Bomfim Aline Biazola Visnardi Tania Churasacari Vinces Alexandre Ceroni Edison Luiz Durigon Cristiane Rodrigues Guzzo Source Type: research
Autoimmune hepatitis following mRNA COVID-19 vaccine
Therapie. 2023 Aug 29:S0040-5957(23)00109-9. doi: 10.1016/j.therap.2022.12.014. Online ahead of print.NO ABSTRACTPMID:37704459 | DOI:10.1016/j.therap.2022.12.014
Source: Therapie - September 13, 2023 Category: Psychiatry & Psychology Authors: Ahmed Zaiem Khouloud Ferchichi Ghozlane Lakhoua Widd Kaabi Imen Aouinti Sana Rebii Debbiche Sarrah Kastalli Lamia Kallel Ons Charfi Sihem El Aidli Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function
Virus Res. 2023 Sep 11:199221. doi: 10.1016/j.virusres.2023.199221. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic is fading, however its etiologic agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues posing - despite the availability of licensed vaccines - a global health threat, due to the potential emergence of vaccine-resistant SARS-CoV-2 variants. This makes the development of new drugs against COVID-19 a persistent urgency and sets as research priority the validation of novel therapeutic targets within the SARS-CoV-2 proteome. Among these, a promising one is the...
Source: Cell Research - September 13, 2023 Category: Cytology Authors: Irene Boniardi Angela Corona Jerome Basquin Claire Basquin Jessica Milia Istv án Nagy Enzo Tramontano Luca Zinzula Source Type: research
Pharma - manufacturing: the unappreciated and overlooked indispensable skill
Curr Opin Immunol. 2023 Sep 11;84:102385. doi: 10.1016/j.coi.2023.102385. Online ahead of print.ABSTRACTThe process of vaccine production, manufacturing, is time-intensive, complex, expensive, and highly technical, requiring close coordination and collaboration among multiple companies with different inputs, from active pharmaceutical ingredients to glass, and specializations, and with the supply chains spread across many countries. Covid-19 pandemic highlighted that neglecting and ignoring the need for a global effort in vaccine manufacturing and delivery can have alarming, and devastating, repercussions, especially when ...
Source: Current Opinion in Immunology - September 13, 2023 Category: Allergy & Immunology Authors: Jenik Radon Grace Pan Source Type: research
Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function
Virus Res. 2023 Sep 11:199221. doi: 10.1016/j.virusres.2023.199221. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic is fading, however its etiologic agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues posing - despite the availability of licensed vaccines - a global health threat, due to the potential emergence of vaccine-resistant SARS-CoV-2 variants. This makes the development of new drugs against COVID-19 a persistent urgency and sets as research priority the validation of novel therapeutic targets within the SARS-CoV-2 proteome. Among these, a promising one is the...
Source: Virus Research - September 13, 2023 Category: Virology Authors: Irene Boniardi Angela Corona Jerome Basquin Claire Basquin Jessica Milia Istv án Nagy Enzo Tramontano Luca Zinzula Source Type: research
COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron
CONCLUSIONS: Our results support the use of AZD1222 and other adenoviral/mRNA vaccine boosters to maintain protection against COVID-19 hospitalization from Omicron subvariants, including in elderly and immunocompromised individuals at increased risk of accelerated waning or severe outcomes.PMID:37704499 | DOI:10.1016/j.vaccine.2023.08.085
Source: Vaccine - September 13, 2023 Category: Allergy & Immunology Authors: Wilhelmine Meeraus Anke L Stuurman Ilgaz Durukal Eduardo Conde-Sousa Andrew Lee Andr é Santa Maria B árbara Emoingt Furtado Mario Ouwens Christen M Gray Douglas Andreas Valverde Hugo Gomes da Silva Sylvia Taylor Source Type: research
